No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat may possibly inhibit the metabolism (CYP 3A4) and consequently increase the plasma concentration of Tadalafil (Adcirca).
Elvitegravir 3A4 and then UGT1A1/3; Cobicistat 3A4 (major) and 2D6 (minor)
Elvitegravir : 2C9 (moderate)
Cobicistat : 3A4 and 2D6 (potent), P-gp, MATE 1, BCRP, OATP1B1 and OATP1B3
Possible increase of adverse effects.
Use this combination with caution.
In patients taking this antiretroviral treatment for at least one week, tadalafil may be initiated at a dose of 20 mg QD and increased to 40 mg QD based on tolerability.
In patients already on tadalafil, stop tadalafil at least 24 hours prior to starting this antiretroviral treatment.
After at least one week following initiation of this antiretroviral treatment, resume tadalafil at a dose of 20 mg QD and increase to 40 mg QD based on tolerability.
Monitor closely clinical efficacy and appearance of adverse effects.
Tadalafil toxicity: hypotension, tachycardia, headache, dizziness, flushing, visual changes (difficulty distinguishing blue and green) and syncope.
Treatment efficacy: symptoms reduction as well as the improvement of fonctional capacity (measured for example by the "6 minutes walk distance" (6MWD).
Tadalafil AUC is increased by 124% when using a dose of tadalafil 20 mg associated with ritonavir (Norvir) 200 mg BID. When a 20 mg dose of tadalafil is administered with ritonavir 500 to 600 mg BID at steady state; there is an increase of only 32% in the AUC and a 30% decrease in the Cmax of tadalafil.
Also with ketoconazole (400 mg), a potent CYP3A4 inhibitor, associated with tadalafil 20 mg: there is an increase in tadalafil AUC and Cmax of 312% and 22% respectively. With ketoconazole (200 mg) and a dose of tadalafil 10 mg, rather there is an increase of 107% and 15% in tadalafil AUC and Cmax.
Precautions: hepatic and renal impairment (CrCl 31-50 ml/min: increases 2 times tadalafil AUC). Age >65 years may also increase tadalafil concentration.
Ref # 2570: Stribild Canadian Product Monograph recommends not to co-administer with tadalafil (Adcirca).
Ref #2914: case report of recurrent priapism with combination of tadalafil and fosamprenavir/ritonavir.